News Qualitest continues growth trajectory, acquires Comply to expand Pharma...

Qualitest continues growth trajectory, acquires Comply to expand Pharma and Digital Health footprint

-

Qualitest, one of the world’s leading AI-powered, engineering-driven software testing and quality assurance companies, has announced the acquisition of Israel-based Comply, a quality assurance specialist in Pharma and Digital Health.

Norm Merritt, CEO, Qualitest, said, “We’ve had our eyes on Comply for a while due to its reputation as a leader in providing software testing services to the growing pharma tech market. That’s why we are excited to bring them into the Qualitest family. We see a lot of potential in the pharma industry, and by integrating Comply’s expertise we can expand Qualitest’s footprint in this hot-growth area.”

Gai Anbar, Founder and CEO, Comply, said, “Qualitest is a global leader in testing, which is why it’s the perfect partner to help us take our testing services worldwide. We have been impressed with Qualitest’s position as the go-to provider for software testing. By joining forces, we can capitalize on our own expertise in providing the highest quality assurance for health and pharma businesses.”

Read full article here

Latest news

Patient-Centric Clinical Trials And The Role Of A Travel Concierge

Many people find booking plane tickets, arranging road transportation and overnight lodging overwhelming. Add into that mix...

China forces insulin price cuts resulting in pullback for global pharma players

Xinhua, a Chinese news channel, commented on the price cut on insulin which was brought on by...

Aussie pharma CSL in talks to buy Swiss firm Vifor Pharma for USD 7B

CSL, the Australian giant, is in talks to buy Vifor Pharma in a deal that is valued...
- Advertisement -

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you